6-methoxy-3,4-dihydro-2H-spiro[isoquinoline-1,4'-piperidine] | 642050-07-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 6-methoxy-3,4-dihydro-2H-spiro[isoquinoline-1,4'-piperidine]
• 英文别名: 6-methoxyspiro[3,4-dihydro-2H-isoquinoline-1,4'-piperidine]
• CAS: 642050-07-5
• 化学式: C₁₄H₂₀N₂O
• 分子量: 232.326
• InChiKey: YAUSJVIQNSVMLN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  33.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-methoxy-3,4-dihydro-2H-spiro[isoquinoline-1,4'-piperidine] 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 生成 1',2',3',4'-Tetrahydro-6'-hydroxy-spiro
  参考文献：
  名称：

  Tetrahydroisoquinolines as MCH-R1 antagonists

  摘要：

  A series of potent and selective inhibitors of h-MCH-R1 has been developed based on the piperidine glycineamide compounds I and II. These structurally more rigid tetrahydroisoquinolines (III and IV) showed better pharmacokinetics. The highly potent compounds 12d and 12g displayed excellent rat pk. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.06.055
• 作为产物：
  描述：

  N-叔丁氧羰基-4-哌啶酮 、 3-甲氧基苯乙胺 在 磷酸 作用下， 生成 6-methoxy-3,4-dihydro-2H-spiro[isoquinoline-1,4'-piperidine]
  参考文献：
  名称：

  Tetrahydroisoquinolines as MCH-R1 antagonists

  摘要：

  A series of potent and selective inhibitors of h-MCH-R1 has been developed based on the piperidine glycineamide compounds I and II. These structurally more rigid tetrahydroisoquinolines (III and IV) showed better pharmacokinetics. The highly potent compounds 12d and 12g displayed excellent rat pk. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.06.055

文献信息

• [EN] INHIBITORS OF 11ß -HYDROXYSTEROID DEHYDROGENASE TYPE 1<br/>[FR] INHIBITEURS DE LA 11?-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE DE TYPE 1
  申请人：VITAE PHARMACEUTICALS INC

  公开号：WO2009108332A1

  公开（公告）日：2009-09-03

  This invention relates to novel compounds of the Formulae I or II and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD l in mammals.Formula (I).

  这项发明涉及到式I或II的新化合物及其药用盐，以及与之相关的药物组合物，用于治疗与哺乳动物中11β-HSD l的调节或抑制相关的疾病。Formula (I)。
• INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1
  申请人：Claremon David A.

  公开号：US20110034455A1

  公开（公告）日：2011-02-10

  This invention relates to novel compounds of the Formula (I*), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of Cortisol in a cell or the inhibition of the conversion of cortisone to Cortisol in a cell.

  这项发明涉及到式(I*)的新化合物，其药用盐以及药物组合物，这些化合物对于治疗与哺乳动物中11β-HSD1的调节或抑制相关的疾病是有用的。该发明还涉及这些新化合物的药物组合物和它们在细胞中减少或控制皮质醇的产生或抑制皮质醇酮转化为皮质醇的方法。
• Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase Type 1
  申请人：Claremon David A.

  公开号：US20110136821A1

  公开（公告）日：2011-06-09

  This invention relates to novel compounds of the Formulae I or II and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD 1 in mammals. Formula (I).

  本发明涉及公式I或II的新化合物及其药学上可接受的盐，以及其制备的药物组合物，用于治疗与哺乳动物中11β-HSD 1的调节或抑制相关的疾病。公式（I）。
• Inhibitors of 11β-hydroxysteroid dehydrogenase type 1
  申请人：Claremon David A.

  公开号：US08383629B2

  公开（公告）日：2013-02-26

  This invention relates to novel compounds of the Formulae I or II and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD 1 in mammals. Formula (I).

  该发明涉及公式I或II的新化合物及其药学上可接受的盐，以及这些化合物的药物组合物，可用于治疗与哺乳动物中11β-HSD 1的调节或抑制有关的疾病。公式（I）。
• INHIBITORS OF 11ß -HYDROXYSTEROID DEHYDROGENASE TYPE 1
  申请人：Vitae Pharmaceuticals, Inc.

  公开号：EP2265588A1

  公开（公告）日：2010-12-29